Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series.

ABSTRACT:

Background

The majority of patients with autoimmune hepatitis (AIH) achieve complete remission with established treatment regiments. In patients with intolerance or insufficient response to these drugs, the remaining options are limited and novel treatment approaches necessary. In primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA) and fibrates have improved prognosis dramatically, but there remains a proportion of patients with refractory disease.In patients with refractory AIH and/or PBC, we used a novel treatment strategy with the anti-B cell activating factor, belimumab. The first three patients had concomitant Sjögren's disease. The connecting element between all three diseases is B cell activation, including elevated levels of the B cell activating factor (B

SUBMITTER: Kolev M 

PROVIDER: S-EPMC9883290 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature